530 studies found for:    "Migraine Disorders"
Show Display Options
Rank Status Study
21 Completed Use Of GW274150 In The Prophylactic Treatment Of Migraine
Conditions: Migraine Disorders;   Migraine
Intervention: Drug: GW274150
22 Completed Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan
Conditions: Migraine Disorders;   Cluster Headache;   Migraine
Intervention: Drug: Sumatriptan Succinate
23 Completed
Has Results
Prevention Study in Adult Patients Suffering From Migraine Headaches
Conditions: Migraine Disorders;   Migraine
Interventions: Drug: GSK1838262;   Drug: Placebo
24 Completed An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Conditions: Migraine Disorders;   Migraine
Intervention: Drug: GW274150
25 Completed
Has Results
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
Conditions: Migraine Disorders;   Migraine
Interventions: Drug: Sumatriptan 25 mg;   Drug: Sumatriptan 50 mg;   Drug: Placebo
26 Completed A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
Conditions: Migraine Disorders;   Migraine
Intervention: Drug: This is a pharmacokinetic study (Treximet)
27 Completed Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
Conditions: Migraine Disorders;   Migraine
Interventions: Drug: sumatriptan succinate/naproxen sodium;   Drug: placebo
28 Completed Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)
Conditions: Familial Hemiplegic Migraine;   Migraine With Aura;   Healthy
Intervention: Drug: CGRP
29 Completed Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
Conditions: Migraine With Aura;   Migraine Without Aura
Intervention: Drug: Laxymig ER (drug)
30 Terminated PRIMA PFO Migraine Trial
Conditions: Migraine;   Migraine With Aura;   Patent Foramen Ovale;   PFO
Intervention: Device: AMPLATZER® PFO Occluder Device
31 Withdrawn Aspirin Resistance in Women With Migraine
Conditions: Episodic Migraine;   Chronic Migraine
Interventions: Drug: Aspirin (acetylsalicylic acid);   Drug: Placebo
32 Completed TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
Conditions: Migraine With or Without Aura;   Migraine Disorders
Interventions: Drug: Combination Product (sumatriptan succinate / naproxen sodium);   Drug: RELPAX(eletriptan) 40mg Tablet
33 Completed Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
Conditions: Migraine With Aura;   Migraine Without Aura
Intervention: Drug: Dronabinol MDI
34 Recruiting IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Conditions: Headache Disorders, Primary;   Migraine With Aura;   Migraine Without Aura;   Tension-Type Headache
35 Recruiting Migraine and Body Composition
Conditions: Migraine With and Without Aura;   Chronic Migraine;   Healthy Controls
36 Completed Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
Conditions: Migraine With Aura;   Migraine Without Aura
Interventions: Drug: Maxalt 10mg MLT plus Caffeine 75mg;   Drug: Maxalt 10mg MLT plus Placebo;   Drug: Placebo + Placebo
37 Completed Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
Conditions: Acute Migraine;   Migraine Headache;   Headache Disorders
Interventions: Drug: Zolmitriptan 5 mg Nasal Spray;   Drug: Eletriptan 40 mg tablet
38 Recruiting Pathway M-1: Sphenopalatine Ganglion Stimulation for the Treatment of Chronic or High Frequency, High Disability Migraine Headache
Conditions: Chronic Migraine;   High Frequency, High Disability Migraine
Intervention: Device: ATI Neurostimulation System
39 Suspended A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
Condition: Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
Interventions: Drug: BGG492;   Drug: Placebo
40 Completed fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?
Conditions: Episodic Migraine;   Chronic Daily Migraine

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years